BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Arthur Klausner will be a panelist at the New York Biotechnology Association's Annual Meeting
News | 04. 17. 2006
